Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3–FOXO1

Nobuhiko Sugito 1,†, Kazuki Heishima 1, Yuko Ito 2 and Yukihiro Akao 1,*

1 United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan; nsugito@gifu-u.ac.jp (N.S.); heishima@gifu-u.ac.jp (K.H.)
2 Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan; an1006@osaka-med.ac.jp
* Correspondence: yakao@gifu-u.ac.jp

Received: 4 October 2020; Accepted: 6 November 2020; Published: 10 November 2020

Simple Summary: Rhabdomyosarcoma (RMS) is a soft tissue sarcoma with embryonal (ERMS) and alveolar (ARMS) features, most frequently found in children. ARMS has the worse prognosis due to the formation of the chimeric PAX3–FOXO1 gene. New therapies are needed for the treatment of ARMS. The aim of this study is to evaluate the anticancer effect of chemically-modified MIR143-3p#12 (CM-MIR143#12) on RMS. The ectopic expression of CM-MIR143#12 induced a cell growth suppression by silencing not only KRAS, AKT, and ERK but also the PAX3–FOXO1 chimeric gene, and KRAS networks could control the expression of chimeric PAX3–FOXO1 in ARMS cells. Moreover, CM-MIR143#12 also silenced NRAS mutant in ERMS RD cells. CM-MIR143#12 can be a new nucleic acid medicine for the treatment of RMS by impairing the RAS networks including PAX3–FOXO1.

Abstract: Rhabdomyosarcoma (RMS) is a soft tissue sarcoma most frequently found in children. In RMS, there are two major subtypes, embryonal RMS (ERMS) and alveolar RMS (ARMS). ARMS has the worse prognosis of the two owing to the formation of the chimeric PAX3–FOXO1 gene. A novel therapeutic method is required for treating ARMS. In our previous study, we found that the ectopic expression of chemically modified MIR143-3p#12 (CM-MIR143#12), which is RNase-resistant and shows the highest anti-proliferation activity among the synthesized MIR143 derivatives that were tested, induces significant cell growth suppression by targeting KRAS, AKT, and ERK in colorectal cancer cells. The expression of MIR143-3p in RMS was dramatically downregulated compared with that of normal tissue. Ectopic expression of CM-MIR143#12 in RMS cells resulted in a significant growth inhibitory effect through the induction of apoptosis and autophagy. Interestingly, we found that CM-MIR143#12 also silenced the expression of chimeric PAX3–FOXO1 directly and, using siR-KRAS or siR-AKT, that KRAS networks regulated the expression of PAX3–FOXO1 in ARMS cells. In ERMS harboring NRAS mutation, CM-MIR143#12 silenced mutated NRAS. These findings indicate that CM-MIR143#12 efficiently perturbed the RAS signaling pathway, including the ARMS-specific KRAS/PAX3–FOXO1 networks.

Keywords: RMS; PAX3-FOXO1; MIR143-3p; KRAS; NRAS

1. Introduction

Rhabdomyosarcoma (RMS) is a soft tissue malignant tumor that develops with the highest frequency in childhood. RMS is classified into two types: embryonal RMS (ERMS) and alveolar RMS (ARMS) [1]. ARMS has a poor prognosis [2] because ARMS cells harbor chromosomal translocation...
(q35;q14) or t(1;13)(q35;q14), which results in the formation of the characteristic chimeric gene through the fusion of PAX3 or PAX7 with FOXO1 that is involved in the pathogenesis of ARMS [3–6]. Approximately 60% of ARMS cases are PAX3–FOXO1-positive and 20% are PAX7–FOXO1-positive [7]. Moreover, it was reported that 40% of clinical ERMS samples have mutations in genes of the FGFR4/RAS pathway [8,9]. Additionally, it was reported that mutations of RAS were found in 22.4% of fusion-negative RMS cases (NRAS, 11.7%; KRAS, 6.4%; HRAS, 4.3%) [8]. RMS cell lines harboring RAS mutation were strongly dependent on the RAS/RAF/MEK pathway. On the other hand, the phenotype of non-mutated RAS in RMS cells depends on other pathways such as PAX3–FOXO1/FGFR4 [10] and PI3K/AKT/mTOR [11]. A novel therapeutic method that systemically inactivates these pathways is thus required for the treatment of RMS [12,13].

MicroRNAs (MIRNAs; MIRs) are a class of small non-coding RNAs that regulate the expression of genes by binding to mRNAs and inhibiting their translation [14,15]. Moreover, there are many reports documenting the roles of MIRNAs in the pathogenesis of cancer [16,17]. In RMS, the most commonly reported MIRNA is MIR206. MIR206 is a muscle-tissue-specific MIRNA that is available as a biomarker of RMS [18] and is involved in muscle differentiation [19,20]. MIR1, which is in the same family as MIR206, showed anticancer effects by targeting PTBP1 and regulating energy metabolism in RMS [21]. MIRNA has the potential to target genes that cannot be targeted by conventional molecularly targeted drugs. Therefore, MIRNA may be used as a new form of therapeutic drug directed toward cancers lacking effective treatment approaches. So far, the focus has been on the development of RNA medicines, i.e., the replacement of tumor suppressor (TS)-MIRNAs that target plural genes involved in growth signaling pathways [22–24]. Among these TS-MIRNAs, MIR143 is a typical representative whose poor expression is associated with a variety of cancers [25–29]. MIR143 is a potential therapeutic drug for RMS because 15% of RMS patients have a mutation in their TP53 gene [9], which encodes one of the transcription factors of the MIR143/145 cluster at chromosome 5q33 [30], resulting in the downregulation of MIR143 expression. Furthermore, MIR143-3p induces apoptosis [31,32] and inhibits proliferation, migration, and invasion in osteosarcoma cells [33,34]. We recently reported that the ectopic expression of the chemically modified MIR143-3p#12 (CM-MIR143#12) induces significant inhibition of cancer cell growth through the targeting of KRAS, AKT, and ERK in colorectal [35], bladder [36], and gastric cancer cells [37]. CM-MIR143#12 was developed from among more than 100 kinds of chemically modified MIR143-3p derivatives. Only the guide strand of wild type MIR143 it was c modified using various chemical modifications, such as 2′-fluorine, 2′-methoxy group, phosphorylation, and phosphorothioate, were used (Figure S1A). Moreover, it is strikingly stable in serum (Figure S1B). CM-MIR143#12 exerts anticancer activity with an IC50 of 1.3 nM in KRAS-mutated DLD-1 cells. Our findings clearly show that the on-target effects of CM-MIR143#12 were manifested by interfering with the expression of KRAS and key genes in KRAS networks such as AKT, ERK1/2, and SOS1. By using CM-MIR143#12, we were able to clearly show the involvement of target genes related to KRAS networks including SOS1 of the KRAS-activating system, and KRAS-positive circuit, which is a recruitment system of KRAS mRNA from PI3K/AKT and MAPK signaling pathways [35].

In this present study, we found that CM-MIR143#12 also silenced the PAX3–FOXO1 chimeric gene, and that KRAS networks could control the expression of chimeric PAX3–FOXO1 in ARMS cells. In addition, CM-MIR143#12 efficiently silenced NRAS mutant in ERMS RD cells. We demonstrated the possibility that CM-MIR143#12 can be a new nucleic acid medicine for the treatment of RMS by efficiently impairing the KRAS networks/PAX3–FOXO1 cascade.

2. Results

2.1. Downregulated Expression of MIR143-3p in RMS Cell Lines

We first evaluated the expression levels of MIR143-3p in RMS cell lines (RD, RMS-YM, Rh30, and Rh41) compared with those in normal skeletal muscle (SKM) cells. The expression of MIR143-3p
was significantly downregulated in all RMS cell lines compared with that in normal SKM cells (Figure 1A).

**Figure 1.** (A) Relative expression levels of MIR143 in normal skeletal muscle (SKM) cells and rhabdomyosarcoma cell lines (RD, Rhabdomyosarcoma (RMS)-YM, Rh30, and Rh41). (B–D) Effects of ectopic expression of CM-MIR143#12 on viability of RMS cells (B; Figure S2C) and expression of KRAS, AKT, ERK1/2 (C; Figure S2D), and levels of PARP, as an apoptotic marker, and LC3B, as an autophagic marker, as estimated using Western blot analysis (D) at 24, 48, 72, and 96 h after transfection of RD and Rh30 cells with CM-MIR143#12 at a concentration of 1 or 10 nM. (E) Hoechst 33,342 staining of Rh30 cells at 72 h after transfection with control RNA (1 nM; left) or CM-MIR143#12 (1 nM; right). Typical apoptotic features, such as chromatin condensation and fragmentation of nuclei, were observed (white arrows). (F) Morphological examination using electron microscopy. Rh30 cells were treated with control RNA or CM-MIR143 (1 nM) for 72 h. N: fragmented nuclei; AV: autophagosome. (G) Immunofluorescence of LC3B at 72 h after transfection of Rh30 cells with CM-MIR143#12 (1 nM). LC3B: green; cytoskeleton (phalloidin): red; nucleus (Hoechst 33342): blue. Results are presented as the mean ± SD; *** p < 0.001.
2.2. Growth Inhibitory Effect of CM-MIR143#12 on RMS Cells

To clarify the functional roles of MIR143-3p in RMS, we next evaluated the growth inhibitory effect of MIR143-3p on RMS cell lines by using a chemically modified MIR143-3p#12 (CM-MIR143#12; Figure S1A), which has a comparatively better affinity for its target genes and better RNase tolerance (Figure S1B). In order to examine the effect of CM-MIR143#12 on the growth of RMS cell lines, we transfected RD, RMS-YM, Rh30, and Rh41 cells with CM-MIR143#12. As shown in Figure S2A, the growth of all RMS cell lines was significantly inhibited at 1 nM CM-MIR143#12 for 72 h. Moreover, CM-MIR143#12 did not affect the growth of normal fibroblast cells (Figure S2B). We then chose RD (ERMS) and Rh30 (ARMS) cell lines to compare its effect on each type of RMS because they represent the two main RMS subtypes which have point mutations at TP53 [38], and because they are the two cell lines that showed the highest sensitivity to CM-MIR143#12 among the analyzed RMS cell lines (Figure S2A). Transfection of either cell line with CM-MIR143#12 induced a significant decrease in the number of viable cells compared with that of the control RNA (Figure 1B and Figure S1SC). Of note, the minimal tested concentration (1 nM) of CM-MIR143#12 was sufficient to induce significant cytotoxicity in both RMS cell lines. To confirm whether CM-MIR143#12 decreased the protein expression levels of KRAS, AKT, and ERK1/2, whose genes are known to be possible targets of MIR143 [35], we examined the protein abundance using Western blot analysis. Expectedly, RD and Rh30 cells transfected with CM-MIR143#12 showed decreased expression levels of KRAS, AKT, and ERK1/2 (Figure 1C and Figure S1D). Furthermore, the RMS cells transfected with CM-MIR143#12 displayed phenotypes of both apoptotic and autophagy, which was also shown by Western blot analysis, which revealed that the transfection with CM-MIR143#12 increased the cleaved form of PARP and the transition of LC3B-I to LC3B-II (Figure 1D). Hoechst 33,342 staining revealed these cells also had morphological changes indicative of apoptosis, such as condensed chromatin and nuclear fragmentation (Figure 1E). Electron microscopy verified the apoptotic changes in the nuclei; interestingly, these cells simultaneously showed autophagic features, i.e., the presence of autophagosomes in the same cell (Figure 1F). Consistent with these morphological changes, immunocytochemistry revealed increased expression of LC3B in certain apoptotic CM-MIR143#12-transfected cells (Figure 1G). Thus, exogenous CM-MIR143#12 likely induced combined autophagy/apoptosis cell death.

2.3. AKT Inhibitor Induced Apoptosis and Autophagy in RMS Cells

We examined the association between cell death and the expression of target genes downregulated by CM-MIR143#12. As a result, the knockdown of KRAS using siR-KRAS slightly inhibited cell growth in both RD and Rh30 cell lines (Figure 2A); however, siR-KRAS did not induce apparent apoptosis in either cell line (Figure 2B). On the other hand, inhibition of the AKT pathway using AKT inhibitor IV significantly suppressed cell growth with apoptosis and autophagy in both cell lines, even at a 1 µM (Figure 2C,D). In addition to AKT inhibitor IV, the knockdown of AKT using siR-AKT showed similar effects, although weaker than the inhibitor (Figure S3). Moreover, the inhibition of cell proliferation and the induction of apoptosis by CM-MIR143#12 was abolished in siR-KRAS-knockdown RD and Rh30 cells (Figure 2E,F). Importantly, siR-KRAS and AKT inhibitor IV induced the downregulation of PAX3–FOXO1 in Rh30 cells (Figure 2B,D). These findings suggest that CM-MIR143#12 induces apoptosis and autophagy by inhibiting the PI3K/AKT pathway, the downstream signal pathway of KRAS.
2.4. CM-MIR-143#12 Inhibits Cell Growth by Silencing NRAS in NRAS-Mutated RD Cell Lines

The RD cell line harbors an NRAS-Q61H mutation (Figure 3A). Of note, in the nucleic acid sequencing of RD cells, the A and T peaks of that point mutation appear to overlap (Figure 3A). Therefore, we examined the steady-state mRNA expression levels of wild type NRAS and NRAS-Q61H...
in RD and Rh30 cells by qPCR. NRAS was heterogeneously expressed with the expression of both wild type NRAS and NRAS-Q61H observed in RD cells (Figure S4). Moreover, MIR143-3p targets NRAS [39]. Then, we verified whether CM-MIR143#12 inhibited the expression of NRAS in RD cells. As expected, the expression of NRAS was downregulated 48 h after the transfection of RD cells with CM-MIR143#12 (Figure 3B). Next, we performed NRAS knockdown to test the effects of NRAS in RD and Rh30 cells. siR-NRAS inhibited cell growth at 0.5 nM in RD cells (Figure 3C). Furthermore, siR-NRAS suppressed the expression levels of NRAS mRNA (Figure 3D). siR-NRAS mainly induced autophagy and upregulated KRAS expression (Figure 3E). In addition, we tested for changes in NRAS-Q61H mRNA levels in siR-NRAS or CM-MIR143#12-transfected RD cells. siR-NRAS decreased the mRNA expression of NRAS-Q61H at 72 h after transfection (Figure 3F). CM-MIR143#12 decreased the mRNA expression of NRAS-Q61H at 48 h, with a feedback-induced increase in the expression after 72 h (Figure 3G). These findings suggested that CM-MIR143#12 may strongly regulate the RAS pathway by silencing not only KRAS but also NRAS-Q61H in NRAS-mutated cells.

2.5. Direct Knockdown of the Pax3-Foxo1 Chimeric Gene By CM-MIR143#12 in Rh30 Cells

Next, we explored the putative target genes of MIR143-3p that would have a significant impact on growth and cell death in RMS using TargetScan. We found that the PAX3–FOXO1 chimeric gene contained sequences with which MIR143-3p could potentially bind. Consistent with the result of in silico analysis, ectopic expression of CM-MIR143#12 significantly decreased the expression of PAX3–FOXO1 protein (Figure 4A). Moreover, the luciferase reporter assay using wild type PAX3–FOXO1 3′UTR sequences showed that CM-MIR143#12 bound to potential target sequences shown in the left part of Figure 4B, resulting in lowered luciferase activity (Figure 4B). On the other hand, the introduction of a mutation in the putative binding site markedly attenuated the inhibitory effect elicited by the ectopic expression of CM-MIR143#12 (Figure 4B). Furthermore, transfection with antagoMIR143 significantly increased the rate of cell viability and restored the expression levels of PAX3–FOXO1, which had been decreased by CM-MIR143#12 (Figure 4C).

2.6. Knockdown of PAX3–FOXO1 Induced Autophagy in RMS Cell Lines

To clarify the potential roles of PAX3–FOXO1 in the CM-MIR143#12-induced cell death, we evaluated the effect of PAX3–FOXO1 knockdown by using siR-PF2 [40]. Transfection with this siRNA, which specifically knocked down the chimeric PAX3–FOXO1 gene (siR-PF2; Figure 4B), significantly inhibited the growth of Rh30 cells (Figure 5A). siR-PF2 mainly induced autophagy with a transition from LC3B-I to LC3B-II, but without PARP cleavage (Figure 5B).

2.7. Tumor-Suppressing Effect of CM-MIR143#12 on Rh30 Cell-Xenografted Mice

To further validate the tumor-suppressing effect of CM-MIR143#12, we performed an in vivo experiment in which CM-MIR143#12 was systemically administered using polyionic copolymers every 3 days (1125 µg/kg/administration), four times in total, to nude mice that had been subcutaneously inoculated with Rh30 cells (Figure S5A). As a result, significant suppression of tumor growth was observed in the group generally injected with CM-MIR143#12 compared with growth in the control group (Figure 6A–C and Figure S5B). Statistically, the effects were obvious because the p-values for the first and second administrations were 0.029 and 0.001, respectively (Figure 6A). There was no difference in body weight between CM-MIR143#12 and control MIRNA-treated groups (Figure 6D). Western blot analysis of the tumor samples showed results similar to those obtained in the in vitro experiment (Figure 6E). These findings indicate that CM-MIR143#12 also exerted potent tumor-suppressing activity by targeting KRAS, AKT, ERK1/2, and PAX3–FOXO1 in vivo.
both wild type NRAS and NRAS-Q61H observed in RD cells (Figure S4). Moreover, MIR143-3p targets NRAS [39]. Then, we verified whether CM-MIR143#12 inhibited the expression of NRAS in RD cells. As expected, the expression of NRAS was downregulated 48 h after the transfection of RD cells with CM-MIR143#12 (Figure 3B). Next, we performed NRAS knockdown to test the effects of NRAS in RD and Rh30 cells. siR-NRAS inhibited cell growth at 0.5 nM in RD cells (Figure 3C). Furthermore, siR-NRAS suppressed the expression levels of NRAS mRNA (Figure 3D). siR-NRAS mainly induced autophagy and upregulated KRAS expression (Figure 3E). In addition, we tested for changes in NRAS-Q61H mRNA levels in siR-NRAS or CM-MIR143#12-transfected RD cells. siR-NRAS decreased the mRNA expression of NRAS-Q61H at 72 h after transfection (Figure 3F). CM-MIR143#12 decreased the mRNA expression of NRAS-Q61H at 48 h, with a feedback-induced increase in the expression after 72 h (Figure 3G). These findings suggested that CM-MIR143#12 may strongly regulate the RAS pathway by silencing not only KRAS but also NRAS-Q61H in NRAS-mutated cells.

Figure 3. (A) Sequence verification of NRAS in RD and Rh30 cells. (B) Time course of protein expression of NRAS in RD cells at 24, 48, 72, and 96 h after transfection with CM-MIR143#12 (1, 10 nM). (C,D,E) Effects of ectopic expression of siR-NRAS on the cell viability of RMS cells (C), the mRNA expression of total NRAS estimated by qPCR analysis (D), and the protein expression of KRAS, NRAS, PARP, and LC3B estimated by Western blot analysis 72 h after treatment of RD (E) and RD cells with siR-NRAS at a concentration of 0.5 or 5 nM (F,G), changes in NRAS-Q61H mRNA levels in siR-NRAS (F) or CM-MIR143#12 (G)-transfected RD cells. Results are presented as the mean ± SD; ** p < 0.01; *** p < 0.001.
The inhibitory effect of knocking down PAX3–FOXO1 was elicited by the ectopic expression of CM-MIR143#12. The knockdown of PAX3–FOXO1 with CM-MIR143#12 (1, 10 nM) resulted in a significant decrease in the protein expression of PAX3–FOXO1 at 72 h after transfection of the cells with siR-PF2 at a concentration of 0.5 or 5 nM. siR-PF2 mainly induced autophagy with LC3B transition from LC3B to LC3B and induced autophagic vacuoles and cell death.

**Figure 4.** (A) Protein expression of PAX3–FOXO1 in Rh30 cells at 24, 48, 72, and 96 h after transfection with CM-MIR143#12 (1, 10 nM). (B) Luciferase activities after co-transfection with control RNA or CM-MIR143#12 and wild type or mutant pMIR vectors having the predictive MIR143 binding site in the 3′UTR of FOXO1. The left part of the figure shows the region of the 3′UTR of human FOXO1 mRNA complementary to the mature MIR143. (C) Effect of combined treatment with antagoMIR143/CM-MIR143#12 on the growth of Rh30 cells. Cells were transfected with control RNA or CM-MIR143#12 (1 nM) + antagoMIR143 (1 nM). Left panel: cell viability; right panel: expression level of PAX3–FOXO1 assessed at 72 h after the transfection. PAX3–FOXO1 was detected using the antibody indicated in bold. Results are presented as the mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001.

**Figure 5.** (A,B) Effects of PAX3–FOXO1 knockdown on cell growth (A) and protein expression levels of PAX3–FOXO1, KRAS, AKT, ERK1/2, PARP, and LC3B in Rh30 cells, as examined by Western blot analysis (B) 72 h after transfection of the cells with siR-PF2 at a concentration of 0.5 or 5 nM. siR-PF2 was synthesized by targeting the fusion sites between exon 7 of PAX3 and exon 2 of FOXO1. The knockdown of PAX3–FOXO1 was performed using siR-PF2 [40]. PAX3–FOXO1 was detected using the antibody indicated in bold. Results are presented as mean ± SD; *** p < 0.001.
Figure 6. (A) Anti-tumor effect of CM-MIR143#12 on Rh30 cell xenografted-tumor model mice. The graph shows a time course of tumor size in mice injected with control RNA or CM-MIR143#12 (n = 5). Arrowheads represent intravenous injections of control RNA or CM-MIR143#12 (1.125 mg/kg/administration) delivered using polyionic copolymers (PIC; 375 µg/administration) every 3 days. (B) Photo of tumors in treated and control groups. (C) Graph showing tumor weight. (D) Graph showing a time course of body weight of mice injected with control RNA or CM-MIR143#12. (E) Panel showing Western blot detection of KRAS, AKT, ERK1/2, and PAX3–FOXO1 proteins expressed in the tumor tissues treated with control RNA or CM-MIR143#12. Relative expression levels of each protein/GAPDH were calculated based on densitometric values of each protein and β-actin. PAX3–FOXO1 was detected using the antibody indicated in bold. Results are presented as the mean ± SD; * p < 0.05; ** p < 0.01.

3. Discussion
We demonstrated that the treatment of ARMS Rh30 cells with CM-MIR143#12 resulted in significant growth suppression via interruption of the KRAS/AKT/PAX3–FOXO1 axis. In addition, CM-MIR143#12
may strongly regulate the RAS pathway by silencing not only KRAS but also NRAS-Q61H in NRAS-mutated RD cells.

MIRNA can be used to potentially target any gene that has been difficult to target using conventional molecular targeted drugs. Moreover, MIRNA can disrupt signal cascades systematically by downregulating the expression of multiple key genes involved in driving signaling cascades. The rationale for the combined treatment of MEK- and PI3K-specific inhibitors in the clinical treatment of RAS-mutated RMS has already been reported [41]. As shown in Figure 3E, siR-NRAS upregulates KRAS expression. This result suggests that silencing NRAS or KRAS alone causes a feedback mechanism to occur in a RAS-positive circuit. In light of this, MIRNAs that may be able to comprehensively inhibit pathways may be able to achieve treatments that are less likely to cause feedback mechanisms. MIR143-3p is a major MIRNA that can be directed against KRAS networks because it targets not only KRAS but also AKT, ERKs [26,42,43], and SOS1 [35]. Therefore, compared with let-7 [44], MIR-217 [45], and others that target KRAS, MIR143-3p suppressed KRAS protein expression more strongly than the others because of the presence of two binding sites for MIR143-3p in the 3′UTR of KRAS mRNA. CM-MIR143#12 is superior in its ability to target MAPK/ERK1/2 and PI3K/AKT as well as upstream KRAS, NRAS, and SOS1 in RAS-mutated RMS. In the current study, tumor suppression was observed in response to an extremely low dose of CM-MIR143#12 in Rh30-xenografted mice.

In our previous study, the knockdown of PAX3–FOXO1 induced autophagy by shifting expression from PKM2 to PKM1 by inhibiting the expression of PTBP1, which regulates the expression of PKM1 and PKM2 as a splicer in ARMS [21], thus suggesting that PAX3–FOXO1 positively contributes to the maintenance of the glycolysis-dominant status. However, the protein expression of PTBP1 was almost unchanged in Rh30 cells transfected with CM-MIR143#12. Thus, another mechanism could exist in the case of CM-MIR143#12-induced autophagy. Of note, this is what distinguishes this result from those of previous reports. MIR143 has been reported to inhibit autophagy [46,47] and the induction of autophagy by CM-MIR143#12 may be one of the processes leading to apoptosis; this is an issue that needs to be clarified in future studies.

CM-MIR143#12 shows anticancer effects by impairing the KRAS signaling networks in many kinds of cancer [35–37,48]. Notably, in the current study, CM-MIR143#12 showed anticancer effects on RMS by targeting the ARMS-specific chimeric gene PAX3–FOXO1, which plays an important role in promoting cell cycle progression in ARMS [40]. Moreover, CM-MIR143#12 downregulated the expression of FGFR4, that is, the downstream of PAX3–FOXO1 (data not shown). These results suggest that the RAS pathway can be more strongly controlled by CM-MIR143#12. Recently, MIRNA delivery via LNP successfully suppressed xenografted tumors [49]. In the current study, we also efficiently inhibited tumor growth by using uPIC, the diameter of which is approximately 20 nm and which was selectively prepared as a charge-matched polyionic complex (Figure S4A) [36,37,50].

Treatment of RMS consists of a combination of chemotherapy and radiotherapy after tumor resection or biopsy. The current main therapy for RMS involves a combination of vincristine, actinomycin D, and cyclophosphamide (VAC). In a recent clinical trial [12,13], molecular targeted drugs were tested. The prognosis was improved in the low-risk group with fusion-negative RMS. Although convalescence was improved, the results were still poor for the PAX3–FOXO1-positive RMS group. Therefore, MIRNA or siRNA are potential new therapeutic drugs that can be directed toward PAX3–FOXO1-positive RMS. RNA medicine against RMS will hopefully be successful when introduced via drug delivery systems (DDS) such as lipid nanoparticles (LNP; [51]) and polymers [52] because blood vessels are abundant in tumor tissues, as we found in the case of the xenograft tumors of Rh30 cells (data not shown). Moreover, CM-MIR143#12, which is RNase-resistant (Figure S1B), remains undegraded in the blood for several hours. There may be potential for CM-MIR143#12 delivery due to the enhancement of blood retention.
4. Materials and Methods

4.1. Cell Culture and Cell Viability

Human ERMS (RD and RMS-YM) and ARMS (SJ-Rh30 [Rh30] and SJ-Rh41 [Rh41]) cell lines were used. The RD cell line was obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. RMS-YM cell lines were obtained from RIKEN CELL BANK (Tsukuba, Japan). ARMS cell lines were provided by Dr. H. Hosoi (Kyoto Prefectural University of Medicine). Eagle’s minimal essential medium was used to culture the human ERMS cell line RD while RPMI-1640 medium was used to culture the human ERMS cell line RMS-YM and the human ARMS cell lines Rh30 and Rh41. All media were supplemented with 10% (v/v) heat-inactivated FBS (Sigma-Aldrich Co, St. Louis, MO, USA) and 2 mM L-glutamine, and the cells were incubated under an atmosphere of 95% air and 5% CO\textsubscript{2} at 37 °C. Cell line authentication was conducted using short tandem repeat (STR) analysis, and the cells were tested for mycoplasma contamination. STR analysis was performed by using primers of TH01, TPOX, vWA, Amelogenin, CSF1PO, D16S539, D7S820, D13S317, D5S818, and D21S11 (GenePrint\textsuperscript{®} 10 System; Promega, Madison WI, USA). Testing for mycoplasma contamination was conducted by exploiting the activity of certain mycoplasmal enzymes (MycoAlert\textsuperscript{™} mycoplasma detection kit; Lonza, Basel, CHE). The number of viable cells was determined using trypan blue dye exclusion assay.

4.2. Transfection Experiments

All cells were seeded in 6-well plates at a concentration of 0.5 × 10\textsuperscript{5} per well (10–30% confluence) one prior to transfection. The mature CM-MIR143\#12, antagoMIR143-3p (mirVanaTM MIRNA inhibitor; Ambion) or siRNAs for KRAS, NRAS, PAX3-FOXO1 (siR-KRAS, siR-NRAS, and siR-PF2, respectively; Invitrogen, Carlsbad, CA), and AKT (siR-AKT; CST) were used for the transfection of the cells, which was achieved using cationic liposomes, Lipofectamine\textsuperscript{TM} RNAiMAX (Invitrogen) according to the manufacturer’s lipofection protocol. The nonspecific control RNA (HSS, Hokkaido, Japan) sequence was 5'-GUAGGAGUAGAAAGGCC-3', which was used as a control for nonspecific effects. The sequence of the CM-MIR143\#12 used in this study was from a previous publication ([35]; Figure S1A). The sequence of siR-KRAS was 5'-AAUGCAUGACAACACUGGAUGACCG-3', siR-NRAS was 5'-UACAGAGUAGCAGUCCAGAAGG-3', and siR-PF2 was 5'-UGAAUUCUGAGGAGGAGG-3'. The effects manifested by the introduction of CM-MIR143\#12, and siRNAs into the cells were assessed at 24, 48, 72, or 96 h after transfection.

4.3. Inhibitor Agents

AKT inhibitor IV (Calbiochem, San Diego, CA, USA) without a drug delivery system was used for treating cells. The effects manifested in the cells by the AKT inhibitor were assessed at 72 h.

4.4. Western Blotting

Whole cells were homogenized in chilled lysis buffer comprising 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 2% protease inhibitor cocktail, and 2% phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich Co., St. Louis, MO, USA) and incubated for 20 min on ice. After centrifugation at 13,000 rpm for 20 min at 4 °C, the supernatants were collected as whole-cell protein samples. Protein contents were measured using a DC Protein assay kit (BIORAD, Hercules, CA, USA). Lysate protein (10 µg) was separated by SDS-PAGE using 10.0% or 12.5% polyacrylamide gels and electroblotted onto Immobilon\textsuperscript{®}-P Transfer PVDF membranes (Millipore, Billerica, MA, USA). After blockage of nonspecific binding sites for 1 h with 20% PVDF Blocking Reagent for Can Get Signal\textsuperscript{®} (TOYOBO Co., LTD., Osaka, Japan) in TBS containing 0.1% Tween 20 (TBS-T), the membrane was incubated overnight at 4 °C with primary antibodies. The next day, the membrane was then washed three times with TBS-T, incubated further with secondary antibodies at room temperature for 1 h, and then washed three times with TBS-T. The immunoblots were visualized by the use of Immobilon\textsuperscript{®} Forte Western HRP Substrate (MILLIPORE). The primary antibodies used are
as follows: anti-AKT, phospho-AKT (Ser473), ERK1/2, phospho-ERK1/2, PARP, LC3B, GAPDH, FOXO1 (Cell Signaling Technology [CST], Inc., Danvers, MA, USA); anti-KRAS (LifeSpan BioScience, Seattle, WA, USA); and anti-PAX3 (R&D systems, Minneapolis, MN, USA). HRP-conjugated goat anti-rabbit and horse anti-mouse IgG (CST) were used as secondary antibodies. GAPDH was used as an internal control. Immunoblot images were acquired by using an ImageQuant™ LAS4000 biomolecular imager (GE Healthcare Life Sciences; Pittsburgh, PA, USA). Original unedited blots can be found at Figure S6.

4.5. Quantitative Real-Time PCR (qPCR)

Total RNA was isolated from cultured cells or tumor tissues using a NucleoSpin miRNA isolation kit (TaKaRa, Otsu, Japan). RNA concentrations and purity were assessed by UV spectrophotometry. RNA integrity was checked by formaldehyde gel electrophoresis. To determine the expression levels of MIR143-3p, we conducted quantitative real-time PCR (qPCR) using TaqMan MicroRNA Assays (Applied Biosystems) and THUNDERBIRD™ Probe qPCR Mix (TOYOBO) according to the manufacturer’s protocol. RNU6B was used as an internal control. For determination of the expression levels of NRAS and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs, total RNA was reverse-transcribed with a PrimeScript RT reagent Kit (TaKaRa). qPCR was then performed with specific primers for each gene using THUNDERBIRD™ Next SYBR qPCR Mix (TOYOBO). The primers for NRAS and GAPDH were as follows: NRAS-sense—5′-CCT CCT CAC TTG GCT GTC TG-3′—and NRAS-antisense—5′-TCA CGT TTG CGG TTT GGT TC-3′; NRAS-common sense—5′-CCC GCC TGT GGT CCT AAA TC-3′—and NRAS wild type-antisense—5′-TCA TGG CAC TGT ACT CTT CT-3′—or NRAS Q61H-antisense—5′-TCA TGG CAC TGT ACT CTT CA-3′; GAPDH-sense—5′-CTG AGA CCG CAG GTC AGG TCC ACC-3′ and GAPDH-antisense—5′-GGA CCC ATG GCA AAT TCC ATG GCA-3′. RNU6B and GAPDH were used as internal controls. The relative expression levels were calculated using the ∆∆Ct method.

4.6. Luciferase Reporter Assay

Searching the TargetScan database (TargetScan Release 7.2 [53]) to find algorithm-based binding sites of MIR143-3p, we found the predicted binding site to be at position 1406–1413 for MIR143-3p in the 3′UTR of FOXO1 mRNA. The sequence region containing the putative binding sequence of MIR143-3p was inserted into a pMIR-REPORT™ Luciferase MIRNA Expression Reporter Vector (Applied Biosystems) according to the manufacturer’s protocol. Moreover, we made other pMIR constructs, including one encompassing a mutated seed sequence for MIR143-3p (wild type, UCAUCUCA; mutant, UCUAGUCA) using a PrimeSTAR® Mutagenesis Basal Kit (TaKaRa). The mutation of the vector was confirmed by sequence analysis. pRL-TK Renilla Luciferase Reporter vector (Promega) was used as an internal control vector. Rh30 cells were seeded into 96-well plates at a concentration of 0.5 × 10^4 per well on the day before the transfection. The cells were co-transfected with either reporter vector (0.01 µg/well each) and 1 nM CM-MIR143#12 or nonspecific non-coding siRNA (Dharmacon, Tokyo, Japan). Luciferase activities were measured at 24 h after co-transfection by using a Dual-Glo Luciferase Assay System (Promega) according to the manufacturer’s protocol. Luciferase activities were reported as the firefly luciferase/Renilla luciferase ratio.

4.7. Hoechst 33342 Staining

Hoechst 33342 (5 µg/mL; Sigma-Aldrich) of transfected Rh30 cells was performed 72 h after transfection. The cells were then incubated at 37 °C for 1 h and thereafter washed with PBS. After the wash, cells were resuspended and examined with an Olympus microscope (Tokyo, Japan) equipped with an epi-illuminator and appropriate filters. The apoptotic cells were characterized by the presence of condensed and/or fragmented nuclei.
4.8. Electron Microscopy

Rh30 cells treated with control RNA or CM-MIR143#12 (1 nM) were harvested and rinsed with PBS. The cells were then fixed for 2 h with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.2 M phosphate buffer (pH 7.4, PB), rinsed in PB, and postfixed in 2% osmium tetroxide for 2 h. After having been washed with PB, the cells were progressively dehydrated by passage through a 10% graded series of 30–100% ethanol and then cleared in QY-1 (Nissin EM, Tokyo, Japan). Thereafter, they were embedded in Epon 812 resin (TAAB Laboratories Equipment, Reading, Aldermaston, Berks, Berks, RG7 8NA, UK), after which thin sections (70 nm thickness) were prepared. Finally, the sections were stained with uranyl acetate and lead citrate and examined by transmission electron microscopy using a Hitachi-7650 (Hitachi, Tokyo, Japan), operating at 80 kV.

4.9. Immunofluorescence (IFC) Study

Cells of each cell type were seeded into the wells of a Lab-Tek II Chamber Slide System (Thermo Fisher Scientific Inc., Waltham, MA, USA). After transfection with a given MIRNA, including control RNA, the cells were immunostained with an anti-LC3B antibody according to the immunofluorescence protocol of CST. Next, the nuclei were stained with Hoechst 33342, and for actin labeling, the cells were incubated with a fluorescent F-actin probe, rhodamine phalloidin (Cytoskeleton Inc., Denver, CO, USA). Finally, the cells were observed with a BIORÉVO fluorescence microscope (Keyence, Osaka, Japan).

4.10. Human Tumor Xenograft Model

Animal experimental protocols were approved by the Committee for Animal Research and Welfare of Gifu University (project identification code: H30-42, 10 April 2018). BALB/cSLC-nu/nu (nude) mice were obtained from Japan SLC (Hamamatsu, Japan). Human rhabdomyosarcoma Rh30 cells were inoculated at 2.0 × 10^6 cells/100 µL per site into the back of each of several mice. The inoculation day was set as Day 0. At 11 days after inoculation, we confirmed the engraftment of the tumors. For administration to the mice, MIRNA was mixed with poly(ethylene glycol)-poly (Ornithine) copolymer (a gift from Professor Kazunori Kataoka of the University of Tokyo) to obtain MIRNA-loaded polyionic copolymers (PIC; unit PIC, uPIC) [50] for delivery of the MIRNA to the tumors. After control RNA or CM-MIR143#12 (1.125 mg/kg per single administration) in 120 µL of 10 mM HEPES had been incubated with 15 µL of PIC, the mixture was injected into the tumor every 3 days. Each group contained 5 mice. In the cases in which the tumors had disappeared, we stopped the injections. The tumor volume was calculated using the following formula: \(0.5236 \times L_1 \times L_2^2\), where \(L_1\) is the long axis and \(L_2\) is the short axis of the tumor. This formula is described in a previous report [22,54].

4.11. RNA Samples from Skeletal Muscle Cells

Skeletal muscle cell total RNA (ScienCell Research Laboratories) was used for qPCR as a noncancerous control.

4.12. Statistics

Each examination was performed in triplicate. For in vitro and in vivo experiments, statistical significance of differences was evaluated by performing the two-sided Student’s t-test. The values were presented as the mean ± standard deviation. A \(p\)-value < 0.05 was considered to indicate statistically significant differences.

5. Conclusions

In conclusion, this study demonstrates targeting of KRAS/NRAS Q61H in RD cells and the KRAS/PAX3–FOXO1 cascade in Rh30 cells using CM-MIR143#12; CM-MIR143#12 could efficiently impair these pathways by silencing key genes in the KRAS/NRAS Q61H/AKT network in RD cells.
or KRAS/AKT/PAX3–FOXO1 network in Rh30 cells (Figure 7). We demonstrated the possibility that CM-MIR143#12 can be a new nucleic acid medicine for the treatment of RMS.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2072-6694/12/11/3312/s1.

- Figure S1: CM-MIR143#12 details.
- Figure S2: Effects of ectopic expression of CM-MIR143#12 on RMS and normal fibroblast cells. Figure S3: Effects of ectopic expression of siR-AKT on RD and Rh30 cells.
- Figure S4: The mRNA expression of wild type or mutation type of NRAS in RD and Rh30 cells.
- Figure S5: Diagram showing the formulation of uPIC with CM-MIR143#12 and changing in the tumor size of each mouse.
- Figure S6: Original unedited blots from primary figures.

**Author Contributions:** Conceptualization, N.S.; methodology, N.S.; validation, N.S., K.H. and Y.I.; formal analysis, N.S.; data curation, N.S.; writing—original draft preparation, N.S.; writing—review and editing, K.H. and Y.A.; supervision, Y.A.; project administration, N.S.; funding acquisition, Y.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development (AMED; 16cm0106202 h0001 to Y.A.).

**Acknowledgments:** We thank Professor Kataoka (University of Tokyo) for giving us the polyionic copolymers (PIC). Moreover, we thank Hosoi (Kyoto Prefectural University of Medicine) for providing us with Rh30 and Rh41 cells. In addition, we thank Kikuchi (Kyoto Prefectural University of Medicine) for his advice our study. This work was carried out with the support of SHIONOGI.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Galili, N.; Davis, R.J.; Fredericks, W.J.; Mukhopadhyay, S.; Rauscher, F.J., 3rd; Emanuel, B.S.; Rovera, G.; Barr, F.G. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. *Nat. Genet.* **1993**, *5*, 230–235. [CrossRef] [PubMed]

2. Missiaglia, E.; Williamson, D.; Chisholm, J.; Wirapati, P.; Pierron, G.; Petel, F.; Concordet, J.P.; Thway, K.; Oberlin, O.; Pritchard-Jones, K.; et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. *J. Clin. Oncol.* **2012**, *30*, 1670–1677. [CrossRef] [PubMed]

3. Fredericks, W.J.; Galili, N.; Mukhopadhyay, S.; Rovera, G.; Bennicelli, J.; Barr, F.G.; Rauscher, F.J., 3rd. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. *Mol. Cell. Biol.* **1995**, *15*, 1522–1535. [CrossRef] [PubMed]

4. Anderson, M.J.; Shelton, G.D.; Cavenee, W.K.; Arden, K.C. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 1589–1594. [CrossRef]

5. Meza, J.L.; Anderson, J.; Pappo, A.S.; Meyer, W.H.; Children’s Oncology, G. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The children’s oncology group. *J. Clin. Oncol.* **2006**, *24*, 3844–3851. [CrossRef]

6. Marshall, A.D.; Grosveld, G.C. Alveolar rhabdomyosarcoma—The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. *Skelet Muscle* **2012**, *2*, 25. [CrossRef]

---

**Figure 7.** Schematic diagram showing the mechanism of growth inhibition by the ectopic expression of CM-MIR143#12 in RD and Rh30 cells.
7. Arnold, M.A.; Barr, F.G. Molecular diagnostics in the management of rhabdomyosarcoma. *Expert Rev. Mol. Diagn.* 2017, 17, 189–194. [CrossRef]

8. Shern, J.F.; Chen, L.; Chmielecki, J.; Wei, J.S.; Patidar, R.; Rosenberg, M.; Ambrogio, L.; Auclair, D.; Wang, J.; Song, Y.K.; et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov.* 2014, 4, 216–231. [CrossRef]

9. Seki, M.; Nishimura, R.; Yoshida, K.; Shimamura, T.; Shiraishi, Y.; Sato, Y.; Kato, M.; Chiba, K.; Tanaka, H.; Hoshino, N.; et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. *Nat. Commun.* 2015, 6, 7557. [CrossRef]

10. Crose, L.E.; Etheridge, K.T.; Chen, C.; Belyea, B.; Talbot, L.J.; Bentley, R.C.; Linardic, C.M. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. *Clin. Cancer Res.* 2012, 18, 3780–3790. [CrossRef]

11. Nakagawa, N.; Kikuchi, K.; Yagyu, S.; Miyachi, M.; Iehara, T.; Tajiri, T.; Sakai, T.; Hosoi, H. Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcoma. *Biochem. Biophys. Res. Commun.* 2019, 512, 524–530. [CrossRef] [PubMed]

12. Hosoi, H. Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. *Pediatr. Int.* 2016, 58, 81–87. [CrossRef] [PubMed]

13. Chen, C.; Dorado Garcia, H.; Scheer, M.; Henssen, A.G. Current and future treatment strategies for rhabdomyosarcoma. *Front. Oncol.* 2019, 9, 1458. [CrossRef] [PubMed]

14. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 1993, 75, 843–854. [CrossRef]

15. Ambros, V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. *Cell* 2003, 113, 673–676. [CrossRef]

16. Akao, Y.; Nakagawa, Y.; Naoe, T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. *Biol. Pharm. Bull.* 2006, 29, 903–906. [CrossRef] [PubMed]

17. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.* 2009, 10, 704–714. [CrossRef] [PubMed]

18. Miyachi, M.; Tsuchiya, K.; Yoshida, H.; Yagyu, S.; Kikuchi, K.; Misawa, A.; Iehara, T.; Hosoi, H. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. *Biochem. Biophys. Res. Commun.* 2010, 400, 89–93. [CrossRef]

19. Taulli, R.; Bersani, F.; Foglizzo, V.; Linari, A.; Vigna, E.; Ladanyi, M.; Tuschl, T.; Ponzetto, C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. *J. Clin. Invest.* 2009, 119, 2366–2378. [CrossRef]

20. Hanna, J.A.; Garcia, M.R.; Go, J.C.; Finkelstein, D.; Kodali, K.; Pagala, V.; Wang, X.; Peng, J.; Hatley, M.E. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. *Cell Death Dis.* 2016, 7, e2256. [CrossRef]

21. Sugito, N.; Taniguchi, K.; Kuranaga, Y.; Ohishi, M.; Soga, T.; Ito, Y.; Miyachi, M.; Kikuchi, K.; Hosoi, H.; Akao, Y. Cancer-specific energy metabolism in rhabdomyosarcoma cells is regulated by microRNA. *Nucleic Acid Ther.* 2017, 27, 365–377. [CrossRef] [PubMed]

22. Noguchi, S.; Iwasaki, J.; Kumazaki, M.; Mori, T.; Maruo, K.; Sakai, H.; Yamada, N.; Shimada, K.; Naoe, T.; Kitade, Y.; et al. Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. *Mol. Ther.* 2013, 21, 1204–1211. [CrossRef] [PubMed]

23. Taniguchi, K.; Sugito, N.; Kumazaki, M.; Shinohara, H.; Yamada, N.; Nakagawa, Y.; Ito, Y.; Otsuki, Y.; Uno, B.; Uchiyama, K.; et al. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. *Cancer Lett.* 2015, 363, 17–27. [CrossRef] [PubMed]

24. Minami, K.; Taniguchi, K.; Sugito, N.; Kuranaga, Y.; Inamoto, T.; Takahara, K.; Takai, T.; Yoshikawa, Y.; Kiyama, S.; Akao, Y.; et al. MiR-145 negatively regulates Warburg effect by silencing KLF4 and PTBP1 in bladder cancer cells. *Oncometarget* 2017, 8, 33064–33077. [CrossRef] [PubMed]

25. Akao, Y.; Nakagawa, Y.; Kitade, Y.; Kinoshita, T.; Naoe, T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. *Cancer Sci.* 2007, 98, 1914–1920. [CrossRef] [PubMed]

26. Noguchi, S.; Mori, T.; Hoshino, Y.; Maruo, K.; Yamada, N.; Kitade, Y.; Naoe, T.; Akao, Y. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. *Cancer Lett.* 2011, 307, 211–220. [CrossRef]
27. Ahmad, I.; Singh, L.B.; Yang, Z.H.; Kalna, G.; Fleming, J.; Fisher, G.; Cooper, C.; Cuzick, J.; Berney, D.M.; Moller, H.; et al. Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br. J. Cancer 2013, 108, 149–154. [CrossRef]

28. Cheng, T.; Hu, C.; Yang, H.; Cao, L.; An, J. Transforming growth factor-beta-induced miR143 expression in regulation of non-small cell lung cancer cell viability and invasion capacity in vitro and in vivo. Int. J. Oncol. 2014, 45, 1977–1988. [CrossRef]

29. Shen, J.Z.; Zhang, Y.Y.; Fu, H.Y.; Wu, D.S.; Zhou, H.R. Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells. Oncol. Rep. 2014, 31, 2035–2042. [CrossRef]

30. Suzuki, H.I.; Yamagata, K.; Sugimoto, K.; Iwamoto, T.; Kato, S.; Miyazono, K. Modulation of microRNA processing by p53. Nature 2009, 460, 529–533. [CrossRef]

31. Liu, H.; Wang, H.; Liu, H.; Chen, Y. Effect of miR-143 on the apoptosis of osteosarcoma cells. Int. J. Clin. Exp. Pathol. 2015, 8, 14241–14246. [PubMed]

32. Li, W.H.; Wu, H.J.; Li, Y.X.; Pan, H.G.; Meng, T.; Wang, X. MicroRNA-143 promotes apoptosis of osteosarcoma cells by caspase-3 activation via targeting Bcl-2. Biomed. Pharmacother. 2016, 80, 8–15. [CrossRef] [PubMed]

33. Sun, X.; Dai, G.; Yu, L.; Hu, Q.; Chen, J.; Guo, W. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci. Rep. 2018, 8, 606. [CrossRef] [PubMed]

34. Hou, Y.; Feng, H.; Jiao, J.; Qian, L.; Sun, B.; Chen, P.; Li, Q.; Liang, Z. Mechanism of miR-143-3p inhibiting proliferation, invasion and expansion of osteosarcoma cells by targeting MAPK7. Artif. Cells Nanomed. Biotechnol. 2019, 47, 2065–2071. [CrossRef]

35. Akao, Y.; Kumazaki, M.; Shinohara, H.; Sugito, N.; Kuranaga, Y.; Tsujino, T.; Yoshikawa, Y.; Kitade, Y. Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. Cancer Sci. 2018, 109, 1455–1467. [CrossRef]

36. Yoshikawa, Y.; Taniguchi, K.; Tsujino, T.; Heishima, K.; Inamoto, T.; Takai, T.; Minami, K.; Azuma, H.; Miyata, K.; Hayashi, K.; et al. Anti-cancer effects of a chemically modified miR-143 on Bladder cancer by either systemic or intravesical treatment. Mol. Ther. Methods Clin. Dev. 2019, 13, 290–302. [CrossRef]

37. Tokumaru, Y.; Tajiri, K.; Sugito, N.; Kuranaga, Y.; Shinohara, H.; Tsujino, T.; Matsushashi, N.; Futamura, M.; Akao, Y.; Yoshida, K. Synthetic miR-143 inhibits growth of HER2-positive gastric cancer cells by suppressing KRAS networks including DDX6 RNA helicase. Int. J. Mol. Sci. 2019, 20, 1697. [CrossRef]

38. Felix, C.A.; Kappl, C.C.; Mitsudomi, T.; Nau, M.M.; Tsokos, M.; Crouch, G.D.; Nisen, P.D.; Winick, N.J.; Helman, L.J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992, 52, 2243–2247.

39. Liu, X.; Zhang, Y.; Wang, S.; Liu, G.; Ruan, L. Loss of miR-143 and miR-145 in condyloma acuminatum promotes cellular proliferation and inhibits apoptosis by targeting NRAS. R Soc. Open Sci. 2018, 5, 172376. [CrossRef]

40. Kikuchi, K.; Tsuchiya, K.; Otabe, O.; Gotob, T.; Tamura, S.; Katsumi, Y.; Yagyu, S.; Tsuhai-Shimizu, S.; Miyachi, M.; Iehara, T.; et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2008, 365, 568–574. [CrossRef]

41. Dolgikh, N.; Hugle, M.; Vogler, M.; Fulda, S. NRAS-mutated rhabdomyosarcoma cells are vulnerable to mitochondrial apoptosis induced by coinhibition of MEK and PI3Kalpha. Cancer Res. 2018, 78, 2000–2013. [CrossRef] [PubMed]

42. Akao, Y.; Nakagawa, Y.; Iio, A.; Naoe, T. Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leuk. Res. 2009, 33, 1530–1538. [CrossRef] [PubMed]

43. Noguchi, S.; Yasui, Y.; Iwasaki, J.; Kumazaki, M.; Yamada, N.; Naito, S.; Akao, Y. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013, 328, 353–361. [CrossRef] [PubMed]

44. Choo, K.B.; Soon, Y.L.; Nguyen, P.N.; Hiew, M.S.; Huang, C.J. MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J. Biomed. Sci. 2014, 21, 95. [CrossRef]

45. Zhao, W.G.; Yu, S.N.; Lu, Z.H.; Ma, Y.H.; Gu, Y.M.; Chen, J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 2010, 31, 1726–1733. [CrossRef]

46. Zhou, J.; Wu, S.; Chen, Y.; Zhao, J.; Zhang, K.; Wang, J.; Chen, S. microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma. Exp. Biol. Med. (Maywood) 2015, 240, 867–875. [CrossRef]
47. Lin, X.T.; Zheng, X.B.; Fan, D.J.; Yao, Q.Q.; Hu, J.C.; Lian, L.; Wu, X.J.; Lan, P.; He, X.S. MicroRNA-143 targets ATG2B to inhibit autophagy and increase inflammatory responses in Crohn’s disease. *Inflamm. Bowel Dis.* 2018, 24, 781–791. [CrossRef]

48. Tsujino, T.; Sugito, N.; Taniguchi, K.; Honda, R.; Komura, K.; Yoshikawa, Y.; Takai, T.; Minami, K.; Kuranaga, Y.; Shinohara, H.; et al. MicroRNA-143/Musashi-2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer. *Cancer Sci.* 2019, 110, 2189–2199. [CrossRef]

49. Gokita, K.; Inoue, J.; Ishihara, H.; Kojima, K.; Inazawa, J. Therapeutic potential of LNP-mediated delivery of miR-634 for cancer therapy. *Mol. Ther. Nucleic Acids* 2019, 19, 330–338. [CrossRef]

50. Watanabe, S.; Hayashi, K.; Toh, K.; Kim, H.J.; Liu, X.; Chaya, H.; Fukushima, S.; Katsushima, K.; Kondo, Y.; Uchida, S.; et al. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. *Nat. Commun.* 2019, 10, 1894. [CrossRef]

51. Suzuki, Y.; Ishihara, H. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid. *Int. J. Pharm.* 2016, 510, 350–358. [CrossRef] [PubMed]

52. Gary, D.J.; Puri, N.; Won, Y.Y. Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. *J. Control. Release* 2007, 121, 64–73. [CrossRef] [PubMed]

53. Target Scan Human. Prediction of microRNA Targets. Available online: http://www.targetscan.org/ (accessed on 9 November 2020).

54. Tang, Y.; Simoneau, A.R.; Liao, W.X.; Yi, G.; Hope, C.; Liu, F.; Li, S.; Xie, J.; Holcombe, R.F.; Jurnak, F.A.; et al. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. *Mol. Cancer Ther.* 2009, 8, 458–468. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).